Targeted therapies in melanoma beyond BRAF : targeting NRAS-mutated and KIT-mutated melanoma - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Current Opinion in Oncology Année : 2020

Targeted therapies in melanoma beyond BRAF : targeting NRAS-mutated and KIT-mutated melanoma

Résumé

Purpose of review: Melanoma treatment have been revolutionized since 2010 by the development of immune checkpoint inhibitors, and, for BRAF-mutated melanoma, targeted therapies based on BRAF and MEK inhibitors, which is a model of effective targeted therapy in cancer. However, patients with BRAF wild type cannot benefit for such treatments. In this review, we will focus on the current clinical development of targeted therapies beyond BRAF, in NRAS-mutated and KIT-altered melanoma. Recent findings: In NRAS-mutated melanoma, targeted therapies based on MEK inhibition are being developed as monotherapy or in combination with MAPK, PI3K or CDK4/6 inhibitor. Targeted therapies of KIT-altered melanoma patients is based in KIT inhibitor (mostly imatinib, nilotinib), although for both melanoma subtypes, results are for now disappointing as compared with BRAF and MEK inhibitors in BRAF-mutated melanoma. Summary: Combined therapeutic targeted strategies are awaited in NRAS-mutated and KIT-altered melanoma and could provide additional benefit.
Fichier non déposé

Dates et versions

inserm-03033443 , version 1 (01-12-2020)

Identifiants

Citer

Julie Delyon, Céleste Lebbe, Nicolas Dumaz. Targeted therapies in melanoma beyond BRAF : targeting NRAS-mutated and KIT-mutated melanoma. Current Opinion in Oncology, 2020, 32 (2), pp.79-84. ⟨10.1097/CCO.0000000000000606⟩. ⟨inserm-03033443⟩

Collections

INSERM UP-SANTE
20 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More